普罗布考联合阿托伐他汀治疗急性脑梗死的疗效分析被引量：1

下载PDF

导出

摘要目的探讨普罗布考联合阿托伐他汀治疗急性脑梗死的疗效.方法按照随机数字表法将80例急性脑梗死患者均分为实验组和对照组,对照组患者给予阿托伐他汀治疗,实验组患者给予普罗布考联合阿托伐他汀治疗,对比2组患者治疗前后HDL-C、LDL-C、MMP-9水平以及NIHSS评分变化情况.结果实验组患者治疗后HDL-C显著高于对照组,LDL-C、MMP-9、NIHSS评分显著低于对照组,差异具有显著性(P＜0.05).结论普罗布考联合阿托伐他汀能够有效改善患者血脂异常和MMP-9水平,改善患者神经功能,临床疗效显著.

作者宋欢欢

机构地区河南科技大学第一附属医院

出处《临床研究》 2016年第7期177-178,共2页 Clinical Research

关键词普罗布考阿托伐他汀急生脑梗死

分类号 R972 [医药卫生—药品]

引文网络
相关文献

参考文献3

1戴真煜,陈飞,姚立正,董从松,刘洋,侍海存,张志平,杨乃忠,张明生,戴迎桂.磁共振扩散张量成像在急性缺血性脑梗死时相判断中的应用[J].中华医学杂志,2015,95(31):2526-2531. 被引量：26
2田春霞.普罗布考联合阿托伐他汀治疗急性脑梗死的临床疗效观察[J].心血管病防治知识（学术版）,2015,5(5):38-39. 被引量：1
3赵晓晖,隋海晶,周媛,夏卫英,白青科,张渊,陈娟,杨娟,朱玉萍.阿托伐他汀与普罗布考联合治疗对脑梗死颈动脉粥样硬化斑块影响的影像学评价[J].中国临床神经科学,2012,20(4):397-401. 被引量：16

二级参考文献35

1Spence JD, Hegele RA. Noninvasive phenotypes of atherosclerosis: similar windows but different views[J]. Stroke,2004,35:649-653.
2Saam T, Ferguson MS, Yamykh VL, et al. Quantitative evaluation of carotid plaque composition by in vivo MRI[J]. Arterioscler Thromb Vasc Biol,2005,25:234-239.
3Fisher M, Paganini-Hill A, Matin A, et al. Carotid plaque pathology: thrombosis, ulceration, and stroke pathogenesis[J]. Stroke,2005, 36:253-257.
4Prabhakaran S, Rundek T, Ramas R, et al. Carotid plaque surface irregularity predicts isehemic stroke: the northern Manhattan Study [J]. Stroke,2006,37:2696-2701.
5Spagnoli LG, Mauriello A, Sangiorgi G, et al. Extracranial thrombotieally active carotid plaque as a risk factor for ischemic stroke[J]. JAMA,2004,292:1845-1852.
6Iqbal M, Sharma SD, Okada S. Probucol as a potent inhibitor of oxygen radical-induced lipid peroxidation and DNA damage:in vitro studies[J]. Redox Rep,2004,9:167-172.
7Weber RA, Hui ES,JensenJH, et al. Diffusional kurtosis and diffusion tensor imaging reveal different time-sensitive stroke-induced microstructural changes[J]. Stroke,2015 ,46(2) :545-550.
8AI-Ali F, EliasJ J, Tomsick TA, et al. Relative Influence of Capillary Index Score, Revascularization, and Time on Stroke Outcomes From the Interventional Management of Stroke m Trial[J] . Stroke,2015,46(6) :1590-1594.
9Akamatsu H, Inoue A, Mitsudomi T, et al. Interstitial lung disease associated with gefitinib inJapanese patients with EGFR?mutated non-small-cell lung cancer: combined analysis of two Phase m trials (NEJ 002 and WJTOG 3405 )[J].JpnJ Clin Oncol, 2013, 43(6) :664-668.
10Zhou C, W u YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation?positive non-small-cell lung cancer ( OPTIMAL, CTONG'f)802) : a multicentre, open-label, randomised, phase 3 study[J]. Lancet Oncol, 2011,12(8) :735-742.